The relationship between long non-coding RNA and renal cell carcinoma and its clinical applications in renal cell carcinoma

doi:10.3877/cma.j.issn.1674-3253.2024.03.016

Abstract

Abstract:

Long non-coding RNAs (lncRNAs) play an important role in the occurrence and development of renal cell carcinoma, regulating cell proliferation, tumorigenesis in vivo, invasion, metastasis in vivo, apoptosis, and therapeutic resistance. Therefore, lncRNAs may serve as diagnostic biomarkers for renal cell carcinoma and new targets for targeted therapy, and also have certain potential in predicting treatment response in renal cell carcinoma.

Key words: lncRNAs, Renal cell carcinoma, Regulation mechanism, Immunotherapy, Targeted therapy

Yonghao Deng, Jiazheng Cao. The relationship between long non-coding RNA and renal cell carcinoma and its clinical applications in renal cell carcinoma[J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(03): 289-293.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhqjmnmwkzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3253.2024.03.016

https://zhqjmnmwkzz.cma-cmc.com.cn/EN/Y2024/V18/I03/289

References 36

[1]	Bahadoram S, Davoodi M, Hassanzadeh S, et al. Renal cell carcinoma: an overview of the epidemiology, diagnosis, and treatment[J]. G Ital Nefrol, 2022, 39(3): 2022-vol3.
[2]	Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European association of urology guidelines on renal cell carcinoma: the 2019 update[J]. Eur Urol, 2019, 75(5): 799-810.
[3]	Makino T, Kadomoto S, Izumi K, et al. Epidemiology and prevention of renal cell carcinoma[J]. Cancers, 2022, 14(16): 4059.
[4]	Govindarajan A, Castro DV, Zengin ZB, et al. Front-line therapy for metastatic renal cell carcinoma: a perspective on the current algorithm and future directions[J]. Cancers, 2022, 14(9): 2049.
[5]	Iaxx R, Lefort F, Domblides C, et al. An evaluation of cabozantinib for the treatment of renal cell carcinoma: focus on patient selection and perspectives[J]. Ther Clin Risk Manag, 2022, 18: 619-632.
[6]	周东杰, 蒋敏, 范海瑞, 等. 非编码RNA在卵泡发育成熟中作用及其机制的研究现状[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(4): 387-393.
[7]	Chi Y, Wang D, Wang J, et al. Long non-coding RNA in the pathogenesis of cancers[J]. Cells, 2019, 8(9): 1015.
[8]	Li M, Jiao L, Shao Y, et al. LncRNA-ZFAS1 promotes myocardial ischemia-reperfusion injury through DNA methylation-mediated Notch1 down-regulation in mice[J]. JACC Basic Transl Sci, 2022, 7(9): 880-895.
[9]	Wang J, Liu Z, Xu Y, et al. Enterobacterial LPS-inducible LINC00152 is regulated by histone lactylation and promotes cancer cells invasion and migration[J]. Front Cell Infect Microbiol, 2022, 12: 913815.
[10]	Zhou C, Wang D, Li J, et al. TGFB2-AS1 inhibits triple-negative breast cancer progression via interaction with SMARCA4 and regulating its targets TGFB2 and SOX2[J]. Proc Natl Acad Sci USA, 2022, 119(39): e2117988119.
[11]	Zhou J, Xu N, Liu B, et al. lncRNA XLOC013218 promotes cell proliferation and TMZ resistance by targeting the PIK3R2-mediated PI3K/AKT pathway in glioma[J]. Cancer Sci, 2022, 113(8): 2681-2692.
[12]	Zhang F, Wang H, Yu J, et al. LncRNA CRNDE attenuates chemoresistance in gastric cancer via SRSF6-regulated alternative splicing of PICALM[J]. Mol Cancer, 2021, 20(1): 6.
[13]	Zhang Y, Luo M, Cui X, et al. Long noncoding RNA NEAT1 promotes ferroptosis by modulating the miR-362-3p/MIOX axis as a ceRNA[J]. Cell Death Differ, 2022, 29(9): 1850-1863.
[14]	Wu R, Hu W, Chen H, et al. A novel human long noncoding RNA SCDAL promotes angiogenesis through SNF5-mediated GDF6 expression[J]. Adv Sci, 2021, 8(18): e2004629.
[15]	Li Z, Ma Z, Xu X. Long non-coding RNA MALAT1 correlates with cell viability and mobility by targeting miR-22-3p in renal cell carcinoma via the PI3K/Akt pathway[J]. Oncol Rep, 2019, 41(2): 1113-1121.
[16]	Zhang H, Li W, Gu W, et al. MALAT1 accelerates the development and progression of renal cell carcinoma by decreasing the expression of miR-203 and promoting the expression of BIRC5[J]. Cell Prolif, 2019, 52(5): e12640.
[17]	Pu Y, Dong Z, Xia Y, et al. LncRNA NONHSAT113026 represses renal cell carcinoma tumorigenesis through interacting with NF-κB/p50 and SLUG[J]. Biomed Pharmacother, 2019, 118: 109382.
[18]	Feng JF, Wang J, Xie G, et al. KMT2B promotes the growth of renal cell carcinoma via upregulation of SNHG12 expression and promotion of CEP55 transcription[J]. Cancer Cell Int, 2022, 22(1): 197.
[19]	Zhang C, Ren X, Zhang W, et al. Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers[J]. Bioengineered, 2020, 11(1): 1112-1123.
[20]	Ren Y, Huang W, Weng G, et al. LncRNA PVT1 promotes proliferation, invasion and epithelial-mesenchymal transition of renal cell carcinoma cells through downregulation of miR-16-5p[J]. Onco Targets Ther, 2019, 12: 2563-2575.
[21]	Ramadoss S, Chen X, Wang CY. Histone demethylase KDM6B promotes epithelial-mesenchymal transition[J]. J Biol Chem, 2012, 287(53): 44508-44517.
[22]	Xia M, Yao L, Zhang Q, et al. Long noncoding RNA HOTAIR promotes metastasis of renal cell carcinoma by up-regulating histone H3K27 demethylase JMJD3[J]. Oncotarget, 2017, 8(12): 19795-19802.
[23]	Gong A, Zhao X, Pan Y, et al. The lncRNA MEG3 mediates renal cell cancer progression by regulating ST3Gal1 transcription and EGFR sialylation[J]. J Cell Sci, 2020, 133(16): jcs244020.
[24]	Troiani M, Colucci M, D’Ambrosio M, et al. Single-cell transcriptomics identifies Mcl-1 as a target for senolytic therapy in cancer[J]. Nat Commun, 2022, 13(1): 2177.
[25]	Wu Q, Yang F, Yang Z, et al. Long noncoding RNA PVT1 inhibits renal cancer cell apoptosis by up-regulating Mcl-1[J]. Oncotarget, 2017, 8(60): 101865-101875.
[26]	Jiang Y, Li W, Yan Y, et al. LINC01094 triggers radio-resistance in clear cell renal cell carcinoma via miR-577/CHEK2/FOXM1 axis[J]. Cancer Cell Int, 2020, 20: 274.
[27]	Song E L, Xing L, Wang L, et al. LncRNA ADAMTS9-AS2 inhibits cell proliferation and decreases chemoresistance in clear cell renal cell carcinoma via the miR-27a-3p/FOXO1 axis[J]. Aging, 2019, 11(15): 5705-5725.
[28]	Barth DA, Drula R, Ott L, et al. Circulating non-coding RNAs in renal cell carcinoma-pathogenesis and potential implications as clinical biomarkers[J]. Front Cell Dev Biol, 2020, 8: 828.
[29]	Wu Y, Wang YQ, Weng WW, et al. A serum-circulating long noncoding RNA signature can discriminate between patients with clear cell renal cell carcinoma and healthy controls[J]. Oncogenesis, 2016, 5(2): e192.
[30]	He ZH, Qin XH, Zhang XL, et al. Long noncoding RNA GIHCG is a potential diagnostic and prognostic biomarker and therapeutic target for renal cell carcinoma[J]. Eur Rev Med Pharmacol Sci, 2018, 22(1):46-54.
[31]	Xie J, Zhong Y, Chen R, et al. Serum long non-coding RNA LINC00887 as a potential biomarker for diagnosis of renal cell carcinoma[J]. FEBS Open Bio, 2020, 10(9): 1802-1809.
[32]	Qu L, Ding J, Chen C, et al. Exosome-transmitted lncARSR promotes sunitinib resistance in renal cancer by acting as a competing endogenous RNA[J]. Cancer Cell, 2016, 29(5): 653-668.
[33]	Pan Y, Lu X, Shu G, et al. Extracellular vesicle-mediated transfer of LncRNA IGFL2-AS1 confers sunitinib resistance in renal cell carcinoma[J]. Cancer Res, 2023, 83(1): 103-116.
[34]	Tang H, Chen H, Yuan H, et al. Comprehensive analysis of necroptosis-related long noncoding RNA to predict prognosis, immune status, and immunotherapeutic response in clear cell renal cell carcinoma[J]. Transl Cancer Res, 2022, 11(12): 4254-4271.
[35]	Zhou L, Fang H, Guo F, et al. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma[J]. J Clin Lab Anal, 2022, 36(8): e24582.
[36]	Pang Y, Wang Y, Zhou X, et al. Cuproptosis-related LncRNA-based prediction of the prognosis and immunotherapy response in papillary renal cell carcinoma[J]. Int J Mol Sci, 2023, 24(2): 1464.

Please choose a citation manager

Content to export